Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab

European Journal of Neurology

Volumn 20, Issue 1, 2013, Pages 87-94

  Rossi, S ^a,b   Motta, C ^a,b   Studer, V ^a,b   De Chiara, V ^a,b   Barbieri, F ^a,b   Monteleone, F ^a,b   Fornasiero, A ^c   Coarelli, G ^c   Bernardi, G ^a,b   Cutter, G ^d   Stuve O ^e,f   Salvetti, M ^c   Centonze, D ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^f UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Immunomodulation; JCV; PML; Rebound; Relapse

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB; REBIF 44; UNCLASSIFIED DRUG;

ADULT; ALLERGY; ARTICLE; BACKACHE; CLINICAL ASSESSMENT TOOL; CONSTIPATION; DETERIORATION; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFECT; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INFLUENZA; INJECTION SITE REACTION; INSOMNIA; LARYNGITIS; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; REMISSION; RISK REDUCTION; TREATMENT DURATION; TREATMENT WITHDRAWAL; VERTIGO;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CEREBRAL CORTEX; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT (HEALTH CARE); PEPTIDES; PILOT PROJECTS; PROSPECTIVE STUDIES; RECURRENCE; SPINAL CORD; STATISTICS, NONPARAMETRIC; TIME FACTORS; YOUNG ADULT;

EID: 84871652136     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2012.03794.x     Document Type: Article

References (26)

1. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
2. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353: 375-381.
3. Lindå H, von Heijne A, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 2009; 361: 1081-1087.
4. Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9: 438-446.
5. Steiner I. PML: underdiagnosed in MS patients on natalizumab. Lancet Neurol 2010; 9: 564.
6. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23.
7. Vellinga MM, Castelijns JA, Barkhof F, et al. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 2008; 70: 1150-1151.
8. Fox RJ, Kappos L. Is natalizumab overshooting its rebound? Neurology 2008; 70: 1073-1074.
9. Killestein J, Vennegoor A, Strijbis EM, et al. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol 2010; 68: 392-395.
10. West TW, Cree BA. Natalizumab dosage suspension: are we helping or hurting? Ann Neurol 2010; 68: 395-399.
11. Kerbrat A, Le Page E, Leray E, et al. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients. J Neurol Sci 2011; 308: 98-102.
12. Ramtahal J, Jacob A, Das K, et al. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. J Neurol 2006; 253: 1160-1164.
13. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58: 840-846.
14. Rudick RA, Polman CH, Cohen JA, et al. Assessing disability progression with the Multiple Sclerosis Functional Composite. Mult Scler 2009; 15: 984-997.
15. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010; 68: 295-303.
16. Lenhard T, Biller A, Mueller W, et al. Immune reconstitution inflammatory syndrome after withdrawal of natalizumab? Neurology 2010; 75: 831-833.
17. Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 2011; 68: 186-191.
18. Comi G. Treatment of multiple sclerosis: role of natalizumab. Neurol Sci 2009; 30: S155-S158.
19. Kaufman MD, Lee R, Norton H. Course of relapsing-remitting multiple sclerosis before, during and after natalizumab. Mult Scler 2011; 17: 490-494.
20. O'Connor PW, Goodman AD, Kappos L, et al. Return of disease activity after cessation of natalizumab therapy in patients with multiple sclerosis. Mult Scler 2009; 15: S240-S241.
21. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011; 76: 1858-1865.
22. Stüve O, Cravens PD, Frohman EM, et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology 2009; 72: 396-401.
23. Fox R, Kappos L, Cree B, et al. Effects of a 24-week natalizumab treatment interruption on clinical and radiologic parameters of multiple sclerosis disease activity: the RESTORE study. Mult Scler 2011; 17: S509.
24. Magraner MJ, Coret F, Navarré A, et al. Pulsed steroid followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study. J Neurol 2011; 258: 1805-1811.
25. Havla J, Gerdes LA, Meinl I, et al. De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol 2011; 58: 1665-1669.
26. Goodman AD, Rossman H, Bar-Or A, et al. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology 2009; 72: 806-812.